Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference

WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
May 09, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through...
May 07, 2024 16:19 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen® and other injectors used for the treatment of anaphylaxisOn track...
April 29, 2024 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film

Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg,...
April 25, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET

WARREN, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
April 12, 2024 16:01 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
April 01, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
March 25, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
March 19, 2024 21:49 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
March 19, 2024 16:01 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...